4D Molecular Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

4D Molecular Therapeutics

08/05/2025 21:43

4D Molecular Therapeutics Inc FDMT.OQ reported a quarterly adjusted loss of 86 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of -66 cents.  The mean expectation of nine analysts for the quarter was for a loss of 86 cents per share. Wall Street expected results to range from $-1.05 to -69 cents per share.

Revenue fell 50% to $14.00 thousand from a year ago; analysts expected $382.57 thousand.

4D Molecular Therapeutics Inc's reported EPS for the quarter was a loss of 86 cents​.

The company reported a quarterly loss of $47.97 million.

4D Molecular Therapeutics Inc shares had fallen by 3.6% this quarter and lost 44.1% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 0.6% in the last three months.​

In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for 4D Molecular Therapeutics Inc is $35.00

This summary was machine generated from LSEG data May 8 at 08:43 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.86
-0.86
Met
Dec. 31 2024
-0.82
-0.90
Missed
Sep. 30 2024
-0.70
-0.79
Missed
Jun. 30 2024
-0.70
-0.63
Beat